Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
American Journal of Cancer Research|November 16, 2023
IL25<sup>+</sup> macrophages are a key determinant of treatment resistance of IL17RB<sup>+</sup> breast cancerYukinori Ozaki, Keiichi Kinowaki, Hidetaka Kawabata, et al.
Breast Cancer (Tokyo, Japan)|June 5, 2012
Nodular fasciitis of the breastTsuguo Iwatani, Hidetaka Kawabata, Daishu Miura, et al.
Chemotherapy|September 7, 2013
Reduction of toxicity by reversing the order of infusion of docetaxel and cyclophosphamideMarie Hanaoka, Hidetaka Kawabata, Tsuguo Iwatani, et al.
Psycho-Oncology|April 12, 2013
Predictive factors for psychological distress related to diagnosis of breast cancerTsuguo Iwatani, Ayako Matsuda, Hidetaka Kawabata, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2010
[Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer]Hidetaka Kawabata, Tsuguo Iwatani, Rie Makuuchi, et al.
Molecular and Cellular Biology|September 11, 2019
<i>ESR1</i>-Stabilizing Long Noncoding RNA <i>TMPO-AS1</i> Promotes Hormone-Refractory Breast Cancer ProgressionYuichi Mitobe, Kazuhiro Ikeda, Takashi Suzuki, et al.
Pathology International|February 17, 2022
TRIM39 is a poor prognostic factor for patients with estrogen receptor-positive breast cancer and promotes cell cycle progressionTakuya Ogura, Kotaro Azuma, Toshihiko Takeiwa, et al.
Clinical Breast Cancer|October 12, 2025
Positive Immunoreactivities of TM9SF1 and EBAG9 are Associated With Poor Prognosis in Patients With Triple-Negative Breast CancerKeiichi Kinowaki, Toshihiko Takeiwa, Kazuhiro Ikeda, et al.
International Journal of Molecular Sciences|November 13, 2021
OCT1 Is a Poor Prognostic Factor for Breast Cancer Patients and Promotes Cell Proliferation via Inducing NCAPHTakuya Ogura, Kotaro Azuma, Junichiro Sato, et al.
Pageof 5